Related Experiment Video
Updated: Jul 6, 2026
15:27
Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development
Published on: July 13, 2014
Should valproate be taken during pregnancy?
Therapeutics and Clinical Risk Management
|March 25, 2008
Summary
Sodium valproate use during pregnancy significantly increases the risk of offspring malformations. Even lower doses showed a statistically significant higher risk compared to other antiepileptic drugs.
Area of Science:
- Obstetrics and Gynecology
- Pediatrics
- Pharmacology
Background:
- Sodium valproate is a commonly prescribed antiepileptic drug.
- Understanding its safety profile during pregnancy is crucial for maternal and fetal health.
- Previous studies have suggested potential risks, necessitating further investigation.
Purpose of the Study:
- To evaluate the rate of fetal malformations in pregnancies exposed to sodium valproate compared to other antiepileptic drugs and no antiepileptic drugs.
- To investigate the dose-dependency of malformation risk associated with sodium valproate.
Main Methods:
- Analysis of data from the Australian Registry of Antiepileptic Drug Use in Pregnancy.
- Comparison of malformation rates across three groups: sodium valproate use, other antiepileptic drug use, and no antiepileptic drug use.
- Statistical analysis to determine significance and dose-response relationships.
Main Results:
- A substantially higher rate of malformed offspring (15.1%) was observed in pregnancies exposed to sodium valproate compared to other antiepileptic drugs (2.3%) or no antiepileptic drugs (2.5%).
- At doses ≤1400 mg/day, the malformation rate was 6.42% and did not appear dose-dependent.
- At doses >1400 mg/day, the malformation rate was 33.9% and appeared to increase with dosage.
Conclusions:
- Sodium valproate use in pregnancy is associated with a significantly higher risk of fetal malformations.
- The risk of malformation appears to be dose-dependent, particularly at higher doses.
- Reappraisal of sodium valproate use in women of childbearing potential and pregnant women is warranted, considering therapeutic alternatives.
Related Concept Videos
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...